IL95407A - Reagent, preparation and method for detecting fibrinolytic activity - Google Patents
Reagent, preparation and method for detecting fibrinolytic activityInfo
- Publication number
- IL95407A IL95407A IL9540790A IL9540790A IL95407A IL 95407 A IL95407 A IL 95407A IL 9540790 A IL9540790 A IL 9540790A IL 9540790 A IL9540790 A IL 9540790A IL 95407 A IL95407 A IL 95407A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- fibrinolytic enzyme
- fibrinolytic
- enzyme
- novo nordisk
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 40
- 230000003480 fibrinolytic effect Effects 0.000 title claims abstract description 32
- 238000001514 detection method Methods 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 33
- 239000000203 mixture Substances 0.000 title claims description 10
- 101710196208 Fibrinolytic enzyme Proteins 0.000 claims abstract description 62
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 230000027455 binding Effects 0.000 claims abstract description 18
- 238000001727 in vivo Methods 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 112
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 112
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 110
- 208000007536 Thrombosis Diseases 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 31
- 239000007924 injection Substances 0.000 claims description 31
- 229950003499 fibrin Drugs 0.000 claims description 26
- 102000009123 Fibrin Human genes 0.000 claims description 25
- 108010073385 Fibrin Proteins 0.000 claims description 25
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 229940088598 enzyme Drugs 0.000 claims description 23
- 230000002285 radioactive effect Effects 0.000 claims description 14
- 102000013566 Plasminogen Human genes 0.000 claims description 10
- 108010051456 Plasminogen Proteins 0.000 claims description 10
- 239000003527 fibrinolytic agent Substances 0.000 claims description 10
- 229940012957 plasmin Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 6
- 208000005189 Embolism Diseases 0.000 claims description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 6
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 6
- 206010047249 Venous thrombosis Diseases 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 229960005356 urokinase Drugs 0.000 claims description 6
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 5
- 208000032843 Hemorrhage Diseases 0.000 claims description 5
- 241000792859 Enema Species 0.000 claims description 4
- 210000001015 abdomen Anatomy 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000007920 enema Substances 0.000 claims description 4
- 229940095399 enema Drugs 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 239000007972 injectable composition Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 2
- 208000000616 Hemoptysis Diseases 0.000 claims description 2
- 206010048620 Intracardiac thrombus Diseases 0.000 claims description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 2
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims description 2
- 208000037486 Postoperative Hemorrhage Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000002528 coronary thrombosis Diseases 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- 208000006750 hematuria Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000000689 upper leg Anatomy 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229940090044 injection Drugs 0.000 description 28
- 238000003384 imaging method Methods 0.000 description 21
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000002414 leg Anatomy 0.000 description 8
- 230000000702 anti-platelet effect Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 230000003187 abdominal effect Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000001732 thrombotic effect Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010023197 Streptokinase Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 210000003111 iliac vein Anatomy 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000001699 lower leg Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 238000011640 AKR mouse Methods 0.000 description 2
- 208000027502 Ankle fracture Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 208000035357 Focal Infection Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 210000003513 popliteal vein Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9726—Tissue plasminogen activator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK408289A DK408289D0 (da) | 1989-08-18 | 1989-08-18 | Diagnostisk reagens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL95407A0 IL95407A0 (en) | 1991-06-30 |
| IL95407A true IL95407A (en) | 1994-07-31 |
Family
ID=8129992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9540790A IL95407A (en) | 1989-08-18 | 1990-08-17 | Reagent, preparation and method for detecting fibrinolytic activity |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5165912A (de) |
| EP (1) | EP0487594B1 (de) |
| JP (1) | JPH04507254A (de) |
| KR (1) | KR920703120A (de) |
| AT (1) | ATE92770T1 (de) |
| AU (1) | AU639940B2 (de) |
| CA (1) | CA2065147A1 (de) |
| CZ (1) | CZ280904B6 (de) |
| DD (1) | DD297064A5 (de) |
| DE (1) | DE69002769T2 (de) |
| DK (2) | DK408289D0 (de) |
| ES (1) | ES2058931T3 (de) |
| FI (1) | FI920669A0 (de) |
| IE (1) | IE65525B1 (de) |
| IL (1) | IL95407A (de) |
| NO (1) | NO920624L (de) |
| NZ (1) | NZ234937A (de) |
| WO (1) | WO1991002546A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US7544500B2 (en) * | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US20080167544A1 (en) * | 2006-12-01 | 2008-07-10 | Cold Spring Diagnostics, Inc. | Compositions And Methods For Locating An Internal Bleeding Site |
| BRPI0913397B8 (pt) * | 2008-06-04 | 2021-05-25 | Grifols Therapeutics Inc | método para preparar plasmina |
| JP5789521B2 (ja) | 2009-03-03 | 2015-10-07 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003231A1 (en) * | 1984-01-23 | 1985-08-01 | Institutt For Energiteknikk | TECHNETIUM-99m COMPOSITION FOR LABELLING PROTEINACEOUS MATERIAL AND METHOD |
| US4659839A (en) * | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| CA1285223C (en) * | 1986-11-10 | 1991-06-25 | New England Deaconess Hospital | Detection of vascular disease |
-
1989
- 1989-08-18 DK DK408289A patent/DK408289D0/da not_active Application Discontinuation
-
1990
- 1990-08-16 EP EP90912800A patent/EP0487594B1/de not_active Expired - Lifetime
- 1990-08-16 AT AT90912800T patent/ATE92770T1/de not_active IP Right Cessation
- 1990-08-16 AU AU62859/90A patent/AU639940B2/en not_active Ceased
- 1990-08-16 ES ES90912800T patent/ES2058931T3/es not_active Expired - Lifetime
- 1990-08-16 DE DE90912800T patent/DE69002769T2/de not_active Expired - Fee Related
- 1990-08-16 DK DK90912800.1T patent/DK0487594T3/da active
- 1990-08-16 DD DD90343498A patent/DD297064A5/de not_active IP Right Cessation
- 1990-08-16 NZ NZ234937A patent/NZ234937A/xx unknown
- 1990-08-16 JP JP2512113A patent/JPH04507254A/ja active Pending
- 1990-08-16 KR KR1019920700340A patent/KR920703120A/ko not_active Application Discontinuation
- 1990-08-16 CA CA002065147A patent/CA2065147A1/en not_active Abandoned
- 1990-08-16 WO PCT/DK1990/000210 patent/WO1991002546A1/en active IP Right Grant
- 1990-08-17 IE IE297790A patent/IE65525B1/en not_active IP Right Cessation
- 1990-08-17 CZ CS904047A patent/CZ280904B6/cs unknown
- 1990-08-17 US US07/569,127 patent/US5165912A/en not_active Expired - Fee Related
- 1990-08-17 IL IL9540790A patent/IL95407A/en not_active IP Right Cessation
-
1992
- 1992-02-17 FI FI920669A patent/FI920669A0/fi not_active Application Discontinuation
- 1992-02-17 NO NO92920624A patent/NO920624L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2058931T3 (es) | 1994-11-01 |
| FI920669A0 (fi) | 1992-02-17 |
| IL95407A0 (en) | 1991-06-30 |
| WO1991002546A1 (en) | 1991-03-07 |
| NZ234937A (en) | 1991-11-26 |
| IE902977A1 (en) | 1991-02-27 |
| NO920624D0 (no) | 1992-02-17 |
| DE69002769T2 (de) | 1993-12-02 |
| US5165912A (en) | 1992-11-24 |
| AU639940B2 (en) | 1993-08-12 |
| AU6285990A (en) | 1991-04-03 |
| CZ404790A3 (en) | 1996-01-17 |
| ATE92770T1 (de) | 1993-08-15 |
| CA2065147A1 (en) | 1991-02-19 |
| DK408289D0 (da) | 1989-08-18 |
| DE69002769D1 (de) | 1993-09-16 |
| NO920624L (no) | 1992-02-17 |
| CZ280904B6 (cs) | 1996-05-15 |
| DD297064A5 (de) | 1992-01-02 |
| DK0487594T3 (da) | 1994-01-03 |
| KR920703120A (ko) | 1992-12-17 |
| EP0487594B1 (de) | 1993-08-11 |
| EP0487594A1 (de) | 1992-06-03 |
| JPH04507254A (ja) | 1992-12-17 |
| IE65525B1 (en) | 1995-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4916070A (en) | Fibrin-specific antibodies and method of screening for the antibodies | |
| KR100406072B1 (ko) | 항혈전제 및 항-폰빌레브란트인자 모노클로날항체 | |
| JP3078315B2 (ja) | アテローム性動脈硬化症プラクの画像診断方法 | |
| JPH0616717B2 (ja) | モノクロナ−ル抗体 | |
| IE76288B1 (en) | Bispecific monoclonal antibodes their production and use | |
| EP1064005B1 (de) | Verwendung des urokinase plasminogen aktivator rezeptors als zielscheibe in der diagnose von micrometastasen | |
| Holvoet et al. | Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits | |
| EP0487594B1 (de) | Mittel zum nachweis einer fibrinolytischen wirkung | |
| WO1988001514A1 (en) | Monoclonal antibodies to fibrin | |
| Kanke et al. | Localization and visualization of pulmonary emboli with radiolabeled fibrin-specific monoclonal antibody | |
| US5225540A (en) | Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life | |
| WO1991017775A1 (en) | 99mTcN3S-CONJUGATED ANTI-FIBRIN MONOCLONAL ANTIBODY AS AN IN VIVO DIAGNOSTIC AGENT FOR IMAGING | |
| JPH06505496A (ja) | 活性因子ｘ１１１の活性化を阻害するための組成物と方法 | |
| AU659092B2 (en) | A composition providing improved clearance of bioactive substances from the bloodstream | |
| Tymkewycz et al. | Imaging of human thrombi in the rabbit jugular vein: I: Comparison of two fibrin-specific monoclonal antibodies | |
| JPH07508103A (ja) | トロンビン−アンチトロンビン３複合体のためのイムノアッセイ及び試験キット | |
| Wasser | Detection of thrombi using a Tc-99m labelled antifibrin monoclonal antibody (MoAb) | |
| Charpie | Monoclonal antibodies specific for single-chain urokinase: applications in targeted thrombolysis | |
| McAfee et al. | Monoclonal antibody against human fibrin for imaging thrombi | |
| Riambau et al. | Evaluation of Indium-111 Antifibrin Monoclonal Antibody Imaging in Deep Venous Thrombosis Diagnosis | |
| MXPA00009153A (en) | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| RH | Patent void |